PCT No. PCT/SE94/00509 Sec. 371 Date Jun. 28, 1994 Sec. 102(e) Date Jun. 28, 1994 PCT Filed May 27, 1994 PCT Pub. No. WO94/27988 PCT Pub. Date Dec. 12, 1994The novel optically pure compounds Na+, Mg2+, Li+, K+, Ca2+ and N+(R)4 salts of (+)-5-methoxy-2-[[(4-methoxy-3,5-dimethyl-2-pyridinyl)methyl]sulfinyl]-1H-benzimidazole or (-)-5-methoxy-2-[[(4-methoxy-3,5-dimethyl-2-pyridinyl)methyl]sulfinyl]-1H-benzimidazole, where R is an alkyl with 1-4 carbon atoms, processes for the preparation thereof and...

The present invention relates to a novel form of 5- methoxy- 2- [[(4- methoxy- 3,5- dimethyl- 2- pyridinyl) methyl] sulfinyl] -1H- benzimidazole, known under the generic name omeprazole. More specifically, it relates to a novel crystalline form of the potassium salt of the (S)- enantiomer of 5- methoxy- 2- [[(4- methoxy- 3,5- dimethyl- 2- pyridinyl) methyl] sulfinyl] -1H- benzimidazole. The present invention also relates to processes for preparing such a form of the potassium salt of (S)- omepra...

The present invention is directed toa combination comprising (3-amino-2- fluoropropyl)phosphinic acid, (2R)-(3-amino-2-fluoropropyl)phosphinic acid, or (2S)-(3- amino-2-fluoropropyl)phosphinic acid, or a pharmaceutically acceptable salt thereof, and omeprazole or esomeprazole, or a pharmaceutically acceptable alkaline salt or hydrate thereof, as well as to the use of said combination for the treatment of GERD.

The present invention relates to a novel form of the (-)-enantiomer of 5-methoxy-2- [[(4-methoxy-3,5-dimethyl-2-pyridinyl)- methyl]sulfinyl]-1H-benzimidazole, i.e S-omeprazole. More specifically, it relates to a novel form of the magnesium salt of the S-enantiomer of omeprazole trihydrate. The present invention also relates to processes for preparing such a form of the magnesium salt of S-omeprazole and pharmaceutical compositions containing it. Furthermore, the present invention also relates to...